|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|4.||Acute Promyelocytic Leukemia
|5.||Blast Crisis (Blast Phase)
|1.||Studzinski, George P: 17 articles (04/2015 - 03/2003)|
|2.||Honma, Yoshio: 16 articles (02/2015 - 01/2002)|
|3.||Kantarjian, Hagop: 15 articles (04/2013 - 04/2006)|
|4.||Grant, Steven: 13 articles (12/2015 - 01/2002)|
|5.||Wang, Xuening: 11 articles (04/2015 - 03/2003)|
|6.||Cortes, Jorge: 11 articles (09/2014 - 04/2006)|
|7.||Estévez, Francisco: 11 articles (07/2012 - 12/2003)|
|8.||Kantarjian, Hagop M: 10 articles (07/2015 - 06/2002)|
|9.||Jabbour, Elias: 10 articles (12/2013 - 11/2006)|
|10.||Koeffler, H Phillip: 9 articles (09/2008 - 02/2003)|
|1.||imatinib (Gleevec)FDA Link
03/01/2008 - "The development of imatinib has changed the management of chronic myeloid leukemia (CML), producing high response rates in most patients. "
04/01/2013 - "Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. "
03/01/2012 - "The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. "
08/01/2014 - "Retrospective review of imatinib monitoring through electronic health records (EHR) can provide valuable insight into the current management of chronic myelogenous leukemia (CML). "
02/14/2013 - "Bcr-Abl(T315I) mutation-induced imatinib resistance remains a major challenge for clinical management of chronic myelogenous leukemia (CML). "
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/01/2015 - "The introduction of protein tyrosine kinase inhibitors (TKIs) in 1998 transformed the management of chronic myeloid leukemia (CML), leading to significantly reduced mortality and improved 5 year survival rates. "
07/01/2008 - "The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia (CML). "
11/01/2006 - "The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. "
01/01/2007 - "The advent of tyrosine kinase inhibitors (TKIs) has ushered in a new era in the management of chronic myelogenous leukemia (CML). "
01/01/2015 - "Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?"
|3.||Cytarabine (Cytosar-U)FDA LinkGeneric
05/01/1983 - "However, Lewis X brown Norway F1 hybrid rats bearing brown Norway myelocytic leukemia in early complete remission are curable with ara-C given in optimum timed sequence. "
04/15/2001 - "Cytosine arabinoside (Ara-C) is widely used to induce remission in adult granulocytic leukemia. "
05/01/1983 - "The fact that the Lewis X brown Norway F1 hybrid rats bearing brown Norway myelocytic leukemia, while relatively refractory to ara-C, are curable with this drug when used in optimum timed sequence in early remission is encouraging for similar clinical trials in humans and suggests some principles for the design of such trials."
04/01/2014 - "Human myeloid leukemia HL-60 cells and cytarabine-resistant variant HL/ara-C20 cells were used in the present study. "
08/02/2010 - "The purpose of this study was to evaluate in vivo a targeted pH-sensitive liposomal formulation tailored to promote the efficient intracellular delivery of 1-beta-d-arabinofuranosylcytosine (ara-C) to human myeloid leukemia cells. "
|4.||Tretinoin (Retinoic Acid)FDA LinkGeneric
04/01/1993 - "Recently, clinical use of retinoic acid in acute pro-myelocytic leukemia (APL) was proposed to induce complete remission in the leukemic cells, which have the t(15:17) of chromosomal anomaly producing a different protein from the normal RAR. "
02/01/1982 - "Our study suggests that retinoic acid may prove to be effective in the treatment of human myeloid leukemia."
07/01/2008 - "Recent studies provide significant insight into why some myeloid leukemias respond dramatically to all-trans retinoic acid mediated differentiation therapy, whereas others do not. "
10/01/1997 - "The -463 G creates a stronger SP1 binding site and retinoic acid (RA) response element (RARE) in the allele termed Sp. In this study, we investigate potential links between MPO genotype, MPO expression level, and myeloid leukemia. "
01/01/2015 - "We investigated widely used, patient-derived myeloid leukemia cell lines with proclivity for differentiation into granulocytes by retinoic acid (RA) and/or monocytes by 1,25-dihyrdroxyvitamin D3 (D3). "
|5.||Interferon-alpha (Interferon Alfa)FDA Link
06/01/2001 - "For the management of chronic myeloid leukemia (CML), prediction or early determination of the response to interferon-alpha (IFN-alpha) treatment is important for identifying nonresponder patients to whom alternative therapy may be proposed. "
03/01/1991 - "alpha-Interferon (IFN-alpha) is important in the management of chronic myelogenous leukemia (CML). "
05/01/1996 - "To improve the management of chronic myeloid leukemia (CML) in a single center, we have used interferon-alpha (IFN-alpha) to treat newly diagnosed Ph-positive CML patients and investigated the factors predictive of a major cytogenetic response. "
12/01/1995 - "To improve the management of chronic myeloid leukemia (CML) in a single center, we used interferon alpha (IFN alpha) to treat newly diagnosed CML patients and investigated the factors predictive of a major cytogenetic response. "
10/01/1996 - "Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha."
08/01/1993 - "An international workshop discussed the data on interferon therapy and attempted to define the role of interferon today in the management of chronic myeloid leukemia."
07/01/1985 - "These myeloid leukemia cell line differentiation factors are thus different from interferon and conventional CSA. "
01/01/1983 - "Prolongation by interferon preparation of the survival time of mice implanted with differentiation-inducible mouse myeloid leukemia cells."
03/01/1998 - "For instance, interferons alpha are an important advanced modality in the management of chronic myelogenous leukemia and can be considered a first-line therapy option in patients who cannot receive or relapse following allogenic bone marrow transplant. "
01/01/1993 - "Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results."
|7.||Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/01/1995 - "A method for the determination of human granulocyte colony-stimulating factor (hG-CSF) activity, based on stimulation of cellular proliferation, was developed using a subclone of the murine myeloid leukemia cell line NFS-60, with an improved sensitivity for hG-CSF, as indicator. "
01/01/1993 - "However, until further randomized studies answer these questions, caution must be exercised to avoid unnecessary stimulation of neutrophil production, and G-CSF should not be given to myeloid leukemia patients with a large number of leukemic cells left."
10/01/2009 - "Cytokine therapy especially with G-CSF (granulocyte colony-stimulating factor) administration, changed the treatment of myeloid leukemia. "
04/01/2008 - "Similar intracellular pathways were induced by G-CSF in a myeloid leukemia NFS-60 cell line that was studied in parallel. "
03/29/2007 - "We conclude that control of forward routing of G-CSF-R is essential for a balanced response of myeloid progenitors to G-CSF and suggest that disturbance of this balance may contribute to myeloid leukemia."
|8.||Busulfan (Busulfex)FDA Link
03/01/1971 - "Management of chronic myeloid leukemia: a five-year survey with a comparison of oral busulfan and splenic irradiation."
01/01/1955 - "[Temporary remission induced by 1,4-dimethylsulfonyloxybutane (myleran) in a case of myeloid leukemia in hemocytoblastic attack]."
11/01/2008 - "Altered gene expression in busulfan-resistant human myeloid leukemia."
01/01/1999 - "Busulfan is a carcinostatic which is used for myelocytic leukemia. "
01/01/1986 - "[Effect of busulfan-treated granulocytic leukemia on pregnancy, labor and the somatic condition of the newborn infant]."
01/01/2014 - "Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations."
01/01/2013 - "Bosutinib in the management of chronic myelogenous leukemia."
03/15/2015 - "The pharmacology, pharmacokinetics, efficacy, and safety of the tyrosine kinase inhibitor (TKI) bosutinib in the management of chronic myeloid leukemia (CML) are reviewed. "
03/01/2009 - "Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation."
|10.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
03/01/2003 - "In this study, we analyzed the influence of cell cycle status manipulations of leukemic cells on Fas-mediated apoptosis using the GM-CSF-dependent human myeloid leukemia cell line AML-193 as a model. "
08/01/1992 - "The use of GM-CSF in clonal disorders of hematopoiesis, such as myelodysplasia or myeloid leukemias, requires caution before such applications can be routinely recommended, and the demonstration of safety in this setting from large randomized trials will be needed. "
01/01/1990 - "Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial."
04/22/2010 - "Granulocyte/macrophage colony-stimulating factor promotes growth, survival, differentiation, and activation of normal myeloid cells and plays an important role in myeloid leukemias. "
02/17/2003 - "Granulocyte/macrophage colony-stimulating factor (GM-CSF) is a key cytokine in myelopoiesis and aberrant expression is associated with chronic inflammatory disease and myeloid leukemias. "
|1.||Drug Therapy (Chemotherapy)
06/01/2014 - "Most of the patients received systemic antiacute myeloid leukemia chemotherapy and the overall response rate was 91.3%, and 56.5% patients experienced complete remission. "
01/01/2012 - " In order to characterize the expression pattern of SALL4, BMI-1 and ABCA3 genes in patients with myeloid leukemia and those who achieved complete remission (CR) after chemotherapy. "
12/01/2009 - "Multidrug resistance (MDR) to chemotherapy is a significant barrier to the effective treatment of chromic myeloid leukemia (CML). "
05/01/2004 - "To observe the clinical efficacy of TCM with supplementing Qi, nourishing Yin and clearing heat principle (SQNYCH) combined with chemotherapy in treating myelocytic leukemia. "
01/01/2013 - "These preclinical studies strongly support the therapeutic potential of ex vivo-generated UCB-NK cells in the treatment of myeloid leukemia after immunosuppressive chemotherapy."
01/01/1995 - "Compatible and incompatible patients with myeloid leukemia did not differ with respect to age, sex, remission status of disease at the time of transplant or incidence of GVHD.(ABSTRACT TRUNCATED AT 250 WORDS)"
03/01/2007 - "This qualitative approached study was aimed at identifying the attention demands experienced by a patient diagnosed with sharp myeloid leukemia submitted to a bone marrow transplants (BMT) following the theoretical reference of attention and attention demands. "
01/01/2002 - "For our preclinical studies, we used the haploidentical C57BL/6 (B6) (H2b) --> ((B6 x DBA/2)F1 (H(2b/d)) murine model with lethally irradiated hosts that had received transplants of T-cell-depleted bone marrow cells and were challenged with the MMD2-8 myeloid leukemia line (H2d) of DBA/2 origin. "
02/15/2004 - "Thus, in HLA-matched sibling HSCT for myeloid leukemia, patients homozygous for C2 alleles receiving a graft from a donor carrying the KIR gene KIR2DS2 have a significantly reduced chance of survival."
08/01/2003 - "In conclusion, suicide adenoviral vectors are proposed as a tool for the purging of Adenoviral-susceptible myeloid leukemia cells contaminating autologous bone marrow grafts."
|3.||Transplantation (Transplant Recipients)
08/01/2014 - "It is concluded that the transplantation of UC-MSC combined with haplo-HSCT has good therapeutic efficacy for patients with refractory/relapsed myeloid leukemia, and may be served as a therapeutic method especially for patients with high risk and without well matched donor."
08/01/2009 - "The development of reduced-intensity preparative regimens and improvements in supportive care now allow older patients with myeloid leukemia a greater opportunity for cure with transplantation. "
01/01/2008 - "This chapter describes an efficient and relevant murine model for myeloid leukemias initiated by oncogenic NRAS using an improved bone marrow transduction/transplantation system. "
08/01/2014 - "This study was purposed to analyse the clinical efficacy of transplantation of umbilical cord mesenchymal stem cells (UC-MSC) combined with haploidentical hematopoietic stem cells (haplo-HSCT) for patients with refractory/relapsed myeloid leukemia. "
10/01/2005 - "Cooperativity between Sox4 and another gene, Mef2c, was subsequently confirmed in transplantation studies, in which deregulated Mef2c expression was shown to accelerate the myeloid leukemia induced by Sox4. "
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
06/01/1993 - "The management of chronic myeloid leukemia (CML) patients who relapse after allogeneic bone marrow transplantation (BMT) is difficult. "
06/01/2008 - "An 11-year-old boy with myelocytic leukemia underwent allogeneic bone marrow transplantation. "
02/01/2004 - "To the best of our knowledge, this report is the first to describe unrelated donor bone marrow transplantation with complete engraftment for an SDS patient with myelogenous leukemia."
08/01/2003 - "The presence and longevity of peripherally expanded donor-derived TCRalphabeta+ mature T lymphocyte clones after allogeneic bone marrow transplantation for adult myeloid leukemias."
12/01/2001 - "Twenty-four patients with myeloid leukemia underwent allogeneic bone marrow transplantation. "
|5.||Stem Cell Transplantation
04/01/2002 - "ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors."
06/01/2011 - "We then designed a 4-arm clinical trial in patients with myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT). "
11/01/2008 - "[Outcome of 24 children with myeloid leukemia who received allogeneic stem cell transplantation]."
06/01/2005 - "Half of all hospital charges accrued to only 12.7% of patients; these patients were more likely to have a diagnosis of myeloid leukemia, to have undergone stem cell transplantation, and to have used the PICU. "
02/01/2005 - "Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation."